Real World Data Helping To Drive Rise Of Novartis' Entresto

 
• By Kevin Grogan

Patients with heart failure on Entresto say they have fewer symptoms and greater quality of life, according to a registry study and Novartis is hoping that this and other real world data will propel the drug towards its peak sales target of $5bn.

Hand holding digital tablet with global network connection technology and modern buildings. Element of this image are furnished by NASA
Entresto real-world data adds to strong clinical package • Source: Shutterstock

More from Cardiovascular

More from Therapy Areas